Tremfya (guselkumab) for the Treatment of Plaque Psoriasis
Tremfya™ (guselkumab) is a biologic approved for the treatment moderate-to-severe plaque psoriasis in...
Trending:
-
![]()
Find out how pharma is fighting respiratory illnesses in the latest Pharma Technology Focus
-
![]()
Will tumor-agnostic drug development help accelerate precision medicine approaches?
-
![]()
Emulate and AstraZeneca announce Organs-on-Chips partnership
-
![]()
LIDDS verifies NanoZolid for controlled release of cancer drugs
-
![]()
Merck’s Keytruda combo could be a winner for NSCLC and other solid tumours
-
![]()
ECCMID 2018: Ribaxamase demonstrates protection of the microbiome following Ceftriaxone treatment
Most Read
- Find out how pharma is fighting respiratory illnesses in the latest Pharma Technology Focus
- Genentech doses first patient in Perjeta and Herceptin Phase 3 study
- Combining antibiotics with immune response to treat antibiotic resistant bacteria
- May’s top news stories
- Algorithm optimises peptides to target drug-resistant bacteria
Company A-Z
Latest Content
June’s top news stories
AstraZeneca’s human monoclonal antibody Imfinzi (durvalumab) improved overall survival in the Phase III CASPIAN trial in first-line extensive-stage small cell lung cancer (SCLC).
Lipaglyn (Saroglitazar) for Treating Hypertriglycerdemia in Type II Diabetes
Lipaglyn (Saroglitazar) is a dual peroxisome proliferator-activated receptor (PPAR) agonist indicated for the treatment of hypertriglyceridemia in Type II diabetics.
Getting Acquainted with the Theory of XRF
This white paper provides a general introduction to X-ray Fluorescence (CRF) spectrometry and XRF analysis. It explains how a spectrometer works and how XRF analysis is achieved.
Mitochondrial Testing Services
Mitochondria are present in every cell of the body. They maintain cell homeostasis by controlling energy production, ion fluxes and the rate-limiting step of steroidogenesis.
May’s top news stories
Novartis reported that the first clinical trial in its Phase III PLATINUM programme for QMF149 has met primary and key secondary endpoints in people with inadequately controlled asthma; and The National Institute of Allergy and Infectious Diseases (NIAID) has reported findings from a Phase I/II clinical trial of Okairos’ AdCh3NSmut1/MVA-NSmut vaccine. Drugdevelopment-technology.com wraps up the key headlines from May 2019.
April’s top news stories
Chinese clinical-stage biopharmaceutical company I-Mab Biopharma and German biotech company MorphoSys have begun the first dosed Phase III clinical study to assess investigational human CD38 antibody TJ202/MOR202 in combination with lenalidomide in patients suffering from relapsed or refractory multiple myeloma; and A small clinical trial by researchers at the University of Edinburgh in the UK has showed that cilostazol and isosorbide mononitrate could prevent recurrence of stroke and vascular dementia. Drugdevelopment-technology.com wraps up the key headlines from April 2019.
Detecting the Presence of Trace Polymorphs and Impurities
In the pharmaceutical industry, the detection of polymorph traces is one of the most important applications of powder x-ray diffraction (PXRD).
Eligen® Technology Mechanism of Action
Emisphere's Eligen® Technology binds a delivery agent with a therapeutic compound without alternation. This process occurs when both agent and compound are in close proximity.
Olumiant (baricitinib) for the Treatment of Moderate-to-Severe Rheumatoid Arthritis
Olumiant® (baricitinib) is one of the first once-daily oral selective JAK1 and JAK2 inhibitors for the treatment of moderate-to-severe active rheumatoid arthritis (RA).
March’s top news stories
Aldeyra Therapeutics reported positive data from the Phase III ALLEVIATE trial that evaluated the efficacy and safety of 0.25% and 0.5% concentrations of reproxalap topical ophthalmic solution to treat patients with allergic conjunctivitis.
Latest News
Read our magazine
Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.
Close
Close
Close
Go Top
